(Figure 1) On this scenario, anti-IL-1 therapies proved the potential of inhibiting proinflammatory caspase-1, pathogenic step characteristic for CMS occurrence, associated with aberrant inflammasome signaling, raising a new horizon for metabolic diseases management. The gene discussed is CASP1; the disease is Other metabolic disease.